


重组抗体

RecombiMAb™



重组抗体

小鼠化重组单克隆抗体

bioxcell.com


 AmyJet Scientific
艾美捷科技

 BioCell

RecombiMAb™ 一抗


RecombiMAb™ 抗体使用小鼠或人类 IgG 恒定区代替典型的大鼠或仓鼠 IgG 恒定区，从而在小鼠和人源化小鼠模型中提高了体内活性并减少了免疫原性。在某些同源小鼠肿瘤模型中，特别是在 BALB/c 小鼠中，重复使用大鼠或仓鼠 IgG 可能会导致超敏反应的并发症。使用 RecombiMAb™ 抗体代替野生型克隆可能会降低抗体的免疫原性并缓解超敏反应。

RecombiMAb™ 抗体还通过确保批次间的高一致性和实验间数据的可重复性，克服了传统制造抗体的局限性。




RecombiMAb™ anti-mouse PD-1 (CD279)
阻断 PD-1 与 PD-L1 的结合

小鼠 PD-L1 被固定在板上，与小鼠 PD-1 和 RMP1-14-CP151 抗体孵育。结合的 PD-1 通过 HRP 偶联系统以 450 nm 处的吸光度进行定量。RMP1-14-CP151 值（紫色方块）被标准化为同种型对照抗体值（灰色圆圈）。




RecombiMAb™ anti-mouse PD-1 (CD279) b
阻断 PD-1 与 PD-L1 的结合

小鼠 PD-L1 被固定在板上，并与小鼠 PD-1 及 RMP1-14-CP157 抗体一起孵育。结合的 PD-1 通过 HRP 偶联系统以 450 nm 处的吸光度进行定量。RMP1-14-CP157 值（紫色方块）标准化为同种型对照抗体值（灰色圆圈）。



RecombiMAb™ anti-mouse PD-1 (CD279)
阻断 PD-1 与 PD-L1 的结合

小鼠 PD-L1 被固定在板上，与小鼠 PD-1 和 29F.1A12-CP159 抗体孵育。结合的 PD-1 通过 HRP 偶联系统以 450 nm 处的吸光度进行定量。29F.1A12-CP159 值（紫色方块）被标准化为同种型对照抗体值（灰色圆圈）。



RecombiMAb™ anti-mouse PD-L1 (B7-H1)
阻断 PD-1 与 PD-L1 的结合

小鼠 PD-L1 被固定在板上，并与小鼠 PD-1 及 10F.9G2-CP168 抗体一起孵育。结合的 PD-1 通过 HRP 偶联系统以 450 nm 处的吸光度进行定量。10F.9G2-CP168 值（紫色方块）标准化为同种型对照抗体值（灰色圆圈）。

靶标	反应种属	亚型	突变	应用类型	克隆号	货号	同型对照
4-1BB (CD137)	Mouse	Mo, IgG1		<i>in vivo</i> activation of 4-1BB	LOB12.3-CP035	CP035	BP0083
4-1BB (CD137)	Mouse	Mo, IgG2a		<i>in vivo</i> activation of 4-1BB	LOB12.3-CP037	CP037	BP0085
4-1BB (CD137)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> activation of 4-1BB	LOB12.3-CP036	CP036	
4-1BB (CD137)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> activation of 4-1BB	LOB12.3-CP038	CP038	
4-1BBL (CD137L)	Mouse	Mo, IgG2a		<i>in vivo</i> 4-1BBL blockade, ELISA	TKS-1-CP040	CP040	BP0085
4-1BBL (CD137L)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> 4-1BBL blockade, ELISA	TKS-1-CP039	CP039	
4-1BBL (CD137L)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> 4-1BBL blockade, ELISA	TKS-1-CP041	CP041	
CD4	Mouse	Mo, IgG2b, κ		<i>in vivo</i> CD4+ T cell depletion, FC, WB	GK1.5-CP127	CP127	BP0086
CD8α	Mouse	Mo, IgG2b, κ		<i>in vivo</i> CD8+ T cell depletion, WB	2.43-CP128	CP128	BP0086
CD8α	Mouse	Mo, IgG2a, κ		<i>in vivo</i> CD8+ T cell depletion, WB	YTS 169.4-CP134	CP134	BP0085
CD16/CD32	Mouse	Mo, IgG2a		<i>in vitro</i> Fc receptor blocking, <i>in vivo</i> Fc receptor blocking	2.4G2-CP025	CP025	BP0085
CD16/CD32	Mouse	Mo, IgG2a	LALA-PG	<i>in vitro</i> Fc receptor blocking, <i>in vivo</i> Fc receptor blocking	2.4G2-CP026	CP026	
CD28	Mouse	Mo, IgG2a		<i>in vivo</i> T cell stimulation/activation, <i>in vitro</i> T cell stimulation/activation	D665-CP042	CP042	BP0085
CD28	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> T cell stimulation/activation, <i>in vitro</i> T cell stimulation/activation	D665-CP043	CP043	
CD40	Mouse	Mo, IgG2a, κ		<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation	FGK4.5-CP133	CP133	BP0085
CD40L (CD154)	Mouse	Mo, IgG2a		<i>in vivo</i> & <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1-CP033	CP033	BP0085
CD40L (CD154)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> & <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1-CP032	CP032	
CD40L (CD154)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> & <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1-CP034	CP034	
CD71 (TfR1)	Mouse	Mo, IgG2a, κ		<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3-CP130	CP130	BP0085
CSF1R (CD115)	Mouse	Mo, IgG2a, κ		<i>in vivo</i> macrophage depletion, <i>in vitro</i> CSF1R neutralization, <i>in vivo</i> monocyte depletion, FC, WB	AFS98-CP131	CP131	BP0085
CTLA-4 (CD152)	Mouse	Mo, IgG1, κ		<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10-CP146	CP146	BP0083
CTLA-4 (CD152)	Mouse	Mo, IgG1		<i>in vivo</i> CTLA-4 neutralization, WB	9D9-CP006	CP006	BP0083
CTLA-4 (CD152)	Mouse	Mo, IgG2a		<i>in vivo</i> CTLA-4 neutralization, WB	9D9-CP007	CP007	BP0085
CTLA-4 (CD152)	Mouse	Mo, IgG2a		<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10-CP011	CP011	BP0085
CTLA-4 (CD152)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10-CP010	CP010	
CTLA-4 (CD152)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> CTLA-4 neutralization, WB	9D9-CP008	CP008	
CTLA-4 (CD152)	Mouse	Mo, IgG2b	LALA-PG	<i>in vivo</i> CTLA-4 neutralization, WB	9D9-CP009	CP009	

靶标	反应种属	亚型	突变	应用类型	克隆号	货号	同型对照
CTLA-4 (CD152)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10-CP012	CP012	
GITR	Mouse	Mo, IgG2a		<i>in vivo</i> GITR stimulation	DTA-1-CP028	CP028	BP0085
GITR	Mouse	Mo, IgG2b		<i>in vivo</i> GITR stimulation	DTA-1-CP030	CP030	BP0085
GITR	Mouse	Mo, IgG2b	LALA-PG	<i>in vivo</i> GITR stimulation	DTA-1-CP031	CP031	
GITR	Mouse	Mo, IgG1	D265A	<i>in vivo</i> GITR stimulation	DTA-1-CP027	CP027	
CD40L (CD154)	Mouse	Mo, IgG2a		<i>in vivo</i> & <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1-CP033	CP033	BP0085
ICOSL (CD275)	Mouse	Mo, IgG2a		<i>in vivo</i> ICOSL neutralization	HK5.3-CP045	CP045	BP0085
ICOSL (CD275)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> ICOSL neutralization	HK5.3-CP044	CP044	
ICOSL (CD275)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> ICOSL neutralization	HK5.3-CP046	CP046	
LAG-3	Mouse	Mo, IgG2a		<i>in vivo</i> LAG-3 neutralization, <i>in vitro</i> LAG-3 neutralization, FC, WB	C9B7W-CP014	CP014	BP0085
LAG-3	Mouse	Mo, IgG1	D265A	<i>in vivo</i> LAG-3 neutralization, <i>in vitro</i> LAG-3 neutralization, FC, WB	C9B7W-CP013	CP013	
LAG-3	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> LAG-3 neutralization, <i>in vitro</i> LAG-3 neutralization, FC, WB	C9B7W-CP015	CP015	
OX40 (CD134)	Mouse	Mo, IgG2a		<i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB	OX86-CP017	CP017	BP0085
OX40 (CD134)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB	OX86-CP016	CP016	
OX40 (CD134)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB	OX86-CP018	CP018	
PD-1 (CD279)	Mouse	Mo, IgG2a, κ	D265A	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP151	CP151	CP150
PD-1 (CD279)	Mouse	Mo, IgG2a, κ	L234A, L235A, P329G (LALA-PG)	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP153	CP153	CP150
PD-1 (CD279)	Mouse	Mo, IgG2a, κ		<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP157	CP157	BP0085
PD-1 (CD279)	Mouse	Mo, IgG1, κ		<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, FC, WB	29F.1A12-CP159	CP159	BP0083
PD-1 (CD279)	Mouse	Mo, IgG1, κ		<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP162	CP162	BP0083
PD-1 (CD279)	Mouse	Mo, IgG2c		<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP003	CP003	BE0366
PD-1 (CD279)	Mouse	Mo, IgG1		<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, IF, WB, FC	29F.1A12-CP004	CP004	BP0083
PD-1 (CD279)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP002	CP002	
PD-1 (CD279)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, IF, WB, FC	29F.1A12-CP005	CP005	
PD-L1 (B7-H1)	Mouse	Mo, IgG1, κ		<i>in vivo</i> PD-L1 blockade, IF, IHC (frozen), FC	10F.9G2-CP168	CP168	BP0083
PD-L1 (B7-H1)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> PD-L1 blockade, IF, IHC (frozen), FC, WB	10F.9G2-CP001	CP001	
PD-L2 (B7-DC)	Mouse	Mo, IgG2a		<i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC (frozen), FC	TY25-CP023	CP023	BP0085
PD-L2 (B7-DC)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC (frozen), FC	TY25-CP022	CP022	
PD-L2 (B7-DC)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC (frozen), FC	TY25-CP024	CP024	
VEGFR-2	Mouse	Mo, IgG2a, κ		<i>in vivo</i> blocking of VEGF/VEGFR-2 signaling, <i>in vitro</i> blocking of VEGFR signaling, WB	C101-CP132	CP132	BP0085
VISTA	Mouse	Mo, IgG2a		<i>in vivo</i> blocking of VISTA signaling, <i>in vitro</i> blocking of VISTA signaling	13F3-CP020	CP020	BP0085
VISTA	Mouse	Mo, IgG1	D265A	<i>in vivo</i> blocking of VISTA signaling, <i>in vitro</i> blocking of VISTA signaling	13F3-CP019	CP019	
VISTA	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> blocking of VISTA signaling, <i>in vitro</i> blocking of VISTA signaling	13F3-CP021	CP021	

RecombiMab™ 同型对照抗体

RecombiMab™ 同型对照抗体是通过重组表达的，确保了批次间的极高一致性和实验间数据的可重复性。

所有 RecombiMab™ 抗体都使用超灵敏 qPCR 筛查小鼠病原体，筛查蛋白质聚集，并保证每毫克含有少于 1 单位的内毒素。

Product Name	Host / Isotype	Mutation(s)	Clone	Catalog #
Human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virus	Human IgG1	L234A, L235A, P329G (LALA-PG)	Palivizumab-CP161	CP161
human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme	Human IgG1	L234A, L235A, P329G (LALA-PG)	N/A-CP149	CP149
Human IgG1 isotype control, anti-respiratory syncytial virus	Human IgG1, κ		Palivizumab-CP169	CP169
Human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozyme	Human IgG4	S228P, L235E, P329G	N/A-CP148	CP148
Human IgG4 (S228P) isotype control, anti-hen egg lysozyme (HEL)	Human IgG4, κ	S228P	N/A-CP147	CP147
Human IgG4 (S228P) isotype control, anti-respiratory syncytial virus	Human IgG4, κ	S228P	Palivizumab-CP152	CP152
Mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme	Mouse IgG2a	D265A	N/A-CP150	CP150
Mouse IgG2a isotype control, unknown specificity	Mouse IgG2a		MOPC-21-CP160	CP160

2018年诺贝尔生理或医学奖得主 - James P. Allis

"我对 Bio X Cell为我们提供的产品与服务完全满意。当有人问我的时候，我总是把 Bio X Cell 推荐给他们。我期待着再与Bio X Cell 合作20年!"

25年来，科学家们一直信赖Bio X Cell，将其作为体内功能级抗体的首选来源。这体现在超过 19,000 篇同行评议的出版物中引用了Bio X Cell的产品。我们知道这个责任是最重要的，并继续致力于生产质量和一致性无与伦比的抗体，艾美捷将与Bio X Cell一道协助全球的合作伙伴，加快研究和发现！



Bio X Cell 中国区总代理：

艾美捷科技

400-6800-868

www.amyjet.com

